|
2006 Announcements 19 Dec 2006
Engages Burrill to progress out-licensing
5 Dec 2006
Partnering Update Presentation
3 Nov 2006
Appendix 3B
3 Nov 2006
Neuren raises $1.6million in SPP
31 Oct 2006
Appendix 4C - quarterly cash flows
23 Oct 2006
Letter to shareholders re SPP extension
20 Oct 2006
Preclinical results show cancer regression
17 Oct 2006
SPP extension
16 Oct 2006
NNZ 2591 positive memory loss reversal results
29 Sep 2006
Notice under section 708A(5)(e) of the Corporations Act
27 Sep 2006
Positive Preclinical Results for NNZ-3006
22 Sep 2006
Update for Shareholders Sept 2006
22 Sep 2006
Neuren Share Purchase Plan Disclosures
19 Sep 2006
Appendix 3B - Placement shares
19 Sep 2006
A$6.0 million Share placement & Share Purchase Plan
12 Sep 2006
Appendix 4D
12 Sep 2006
Interim Report 2006
4 Sep 2006
Glypromate® Phase 2 Trial with US Army
22 Aug 2006
Glypromate® Phase 2 trial final results
21 Aug 2006
Neuren adopts IFRS
14 Aug 2006
Neuren presentation to US Army conference
14 Aug 2006
Neuren to present NNZ-2566 Phase 2 Strategy
2 Aug 2006
Neuren selects candidate for oral treatment of Parkinsons
31 Jul 2006
Appendix 4C - quarterly cash flows
21 Jul 2006
Appendix 3B
18 Jul 2006
Neuren appoints Chief Operating Officer
11 Jul 2006
Nerve Protection Compounds Research Published
2 Jun 2006
Change of Director's Interest Notice
29 May 2006
Further US Army results presented on NNZ-2566
11 May 2006
Neuren granted US patent for NNZ-2566
4 May 2006
Change of Director's Interest Notice
4 May 2006
Change of Director's Interest Notice
3 May 2006
Results of AGM
3 May 2006
Neuren AGM CEO Presentation
28 Apr 2006
Appendix 4C - quarterly cash flows
26 Apr 2006
CEO Pipeline & Strategy Update
26 Apr 2006
Neuren & US Army NNZ 2566 brain seizure results
12 Apr 2006
Neuren reports successful Phase 2 results
4 Apr 2006
Presentation to US Conferences
31 Mar 2006
Notice of Annual General Meeting
31 Mar 2006
Annual Report 2005
22 Mar 2006
Preclinical results for oral administration of NNZ-2566
6 Mar 2006
NNZ-2566 Phase 1 trial to commence
28 Feb 2006
Appendix 4E Preliminary Final Report
16 Feb 2006
Neuren & Metabolic report promising data in NRP project
7 Feb 2006
Investor Update February 2006
1 Feb 2006
FDA pre-clinical requirements to Phase 3 completed
31 Jan 2006
Appendix 4C - quarterly cash flows
25 Jan 2006
Appendix 3B - End of Restriction Period
|
